Mir Lim

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

Drug Administration

Top Venues

JCO precision oncology

Cancer research communications

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Stephanie L Alden, Mir Lim, Chester Kao, Daniel H Shu, Amit G Singal, Anne M Noonan, Paige Griffith, Nilofer S Azad, Won Jin Ho, Ihab R Kamel, Mark Yarchoan, David Hsiehchen
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer research communications 3 (7) (2023)
Mir Lim, Patrick T Lynch, Xiaochen Bai, David Hsiehchen
Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding. JCO precision oncology 7 (2023)
Mir Lim, Patrick T Lynch, Xiaochen Bai, David Hsiehchen
Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding. JCO precision oncology 7 (2023)
Mir Lim, Maishara Muquith, Bernadette Miramontes, Magdalena Espinoza, David Hsiehchen
Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma. Cancer research communications 3 (9) (2023)
Mir Lim, David S Shulman, Holly Roberts, Anran Li, Jessica Clymer, Kira Bona, Hasan Al-Sayegh, Clement Ma, Steven G DuBois
Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer medicine 9 (18) (2020)